| Filed On | Filing |
|---|---|
| 10 Nov 2026 | SCHEDULE 13G |
| 04 Nov 2026 |
Form 4: Matsuda Masaru, EVP, Chief Legal Officer
Sold 1,219 shares ($38.8K) · Received 40,000 shares by exercise or conversion ($146K) · Sold 40,000 shares ($1.37M) |
| 04 Nov 2026 |
Form 3: Lisicki Robert, EVP, Chief Commercial Officer
Holds 55,000 shares of Common Stock |
| 04 Nov 2026 |
Form 4: Burnett Patrick, EVP, Chief Medical Officer
Sold 943 shares ($30K) |
| 04 Nov 2026 |
Form 3/A: Scott Robert A, Director
Holds 17,523 shares of Common Stock |
| 04 Nov 2026 |
Form 4: Watanabe Todd, Director
Sold 4,377 shares ($139K) |
| 04 Nov 2026 | 144 |
| 04 Nov 2026 | 424B5 |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Westlake Village, CA, November 4, 2026 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for ... |
| 02 Nov 2026 | 144 |
| 02 Nov 2026 | 144 |
| 02 Nov 2026 | 144 |
| 28 Oct 2026 |
Form 3: Scott Robert A, Director
No securities owned |
| 28 Oct 2026 |
Form 4: Scott Robert A, Director
Received 2,819 shares as a grant or award · Granted 29,170 Stock Option (right to buy) |
| 28 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Exhibit 99.1 FOR IMMEDIATE RELEASE Arcut is Appoints Rob Scot t, MD to Board of Directors WESTLAKE VILLAGE, Calif., Oct . 28, 2026 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on de... |
| 20 Oct 2026 | 144 |
| 19 Oct 2026 |
Form 4: Welgus Howard G., Director
Received 4,094 shares by exercise or conversion ($32.5K) · Sold 4,728 shares ($127K) |
| 15 Oct 2026 | 144 |
| 05 Oct 2026 | SCHEDULE 13G/A |
Loading...